Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Hsu, Chiun; Lee, M.S.; Lee, K.-H.; Numata, K.; Stein, S.; Verret, W.; Hack, S.; Spahn, J.; Liu, B.; C., Huang,; He, R.; Ryoo, B.-Y.

doi:10.1093/annonc/mdz446.006

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arm A of NCT02715531 was a single-arm phase Ib study of the combination of atezolizumab (a PD-L1 antibody) and bevacizumab (a VEGF antibody) in unresectable hepatocellular carcinoma. Updated results from the 104 unresectable hepatocellular carcinoma patients in Arm A were presented at the annual meeting of the European Society for Medical Oncology (ESMO) in Barcelona, in the fall of 2019 [33]. Fifty-three percent of patients had macroscopic vascular invasion (MVI), of whom 88% were hepatocellular carcinoma patients with highly advanced extrahepatic spread (EHS).…”

Section: Classification Of the Tumor Microenvironment And Determination Of Immunotherapeutic Strategiesmentioning

confidence: 99%

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Kudo

2020

Cancers

144

133

View full text Add to dashboard Cite

A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell death-1 (PD-1) antibodies, have failed to show efficacy as first- and second-line therapeutics, respectively, in phase III clinical trials. Immunotherapy with a combination of atezolizumab and bevacizumab resulted in better survival than treatment with sorafenib for the first time since sorafenib was approved in 2007. The high efficacy of the combination of PD-1/programmed death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) antibodies is not only due to their additive effects on tumor growth, but also to their reprogramming of the immunosuppressive microenvironment into an immunostimulatory microenvironment. These results were confirmed in a phase Ib trial that showed significantly longer progression-free survival in the atezolizumab plus bevacizumab group than in patients that received atezolizumab alone. These results demonstrate that immunotherapy with a combination of PD-1/PD-L1 and VEGF inhibitors is effective and may result in a reprogramming of the tumor microenvironment. The results of an ongoing phase III trial of a PD-1 antibody in combination with the VEGF receptor tyrosine kinase inhibitor (TKI) are highly anticipated.

show abstract

Section: Classification Of the Tumor Microenvironment And Determination Of Immunotherapeutic Strategiesmentioning

confidence: 99%

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Kudo

2020

Cancers

144

133

View full text Add to dashboard Cite

show abstract

“…Since then, until the emergence of atezolizumab in combination with bevacizumab, no treatment has surpassed the first-line efficacy of sorafenib[ 18 , 85 ]. In a phase 1b randomized cohort trial comprising 119 patients, atezolizumab in combination with bevacizumab resulted in significantly higher mPFS (7 mo) and ORR (36%) than atezolizumab monotherapy[ 86 ]. In the IMbrave150 clinical trial (NCT03434379) (Table 4 ), compared with sorafenib, the combination of atezolizumab (PD-L1) and bevacizumab (a vascular epidermal growth factor inhibitor) reduced the risk of death by 42% and extended mPFS and mOS by 2.5 and 5.8 mo (median follow-up 15.6 mo), respectively.…”

Section: Combination Of Immune Agents and Anti-angiogenic Drug Therapiesmentioning

confidence: 99%

Immunotherapy for advanced or recurrent hepatocellular carcinoma

Luo¹,

Zhu²

2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is associated with high morbidity and mortality, and is prone to intra- and extrahepatic metastasis due to the anatomical and functional characteristics of the liver. Due to the complexity and high relapse rate associated with radical surgery or radiofrequency ablation, immune checkpoint inhibitors (ICIs) are increasingly being used to treat HCC. Several immunotherapeutic agents, along with their combinations, have been clinically approved to treat advanced or recurrent HCC. This review discusses the leading ICIs in practice and those currently undergoing randomized phase 1–3 trials as monotherapy or combination therapy. Furthermore, we summarize the rapidly developing alternative strategies such as chimeric antigen receptor-engineered T cell therapy and tumor vaccines. Combination therapy is a promising potential treatment option. These immunotherapies are also summarized in this review, which provides insights into the advantages, limitations, and novel angles for future research in establishing viable and alternative therapies against HCC.

show abstract

“…The combination of atezolizumab and bevacizumab showed a promising antitumor ability with acceptable side effect in treatment of untreated unresectable hepatocellular carcinoma. The reported response rate was 36%, and the median progression free survival was 7 months ( 141 ). Another global, multicenter, phase 3 randomized trial, IMbrave150 showed us inspiring results.…”

Section: Treatmentmentioning

confidence: 99%

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Luo

Ding

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of most prevalent cancer and is a serious healthcare issue worldwide. Portal vein tumor thrombus (PVTT) is a frequent complication and remains as the blockage in the treatment of HCC with high recurrence rate and poor prognosis. There is still no global consensus or standard guideline on the management of HCC with PVTT. In western countries, Sorafenib and Lenvatinib are recommended as the first-line treatment options for HCC patients with PVTT where this condition is now regarded as BCLC Stage C regardless of PVTT types. However, there is growing evidence that supports the close relationship of the extent of PVTT to the prognosis of HCC. Besides the targeted therapy, more aggressive treatment modalities have been proposed and practiced in the clinic which may improve the prognosis of HCC patients with PVTT and prolong the patients’ survival time, such as transarterial chemoembolization, radiotherapy, hepatic resection, liver transplantation, and various combination therapies. Herein, we aim to review and summarize the advances in the treatment of HCC with PVTT.

show abstract

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Cited by 12 publications

References 0 publications

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Immunotherapy for advanced or recurrent hepatocellular carcinoma

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Contact Info

Product

Resources

About